The emerging landscape of germline variants in urothelial carcinoma: Implications for genetic testing

Siegel, 2019, Cancer statistics, 2019, CA Cancer J. Clin., 69, 7, 10.3322/caac.21551 Burger, 2013, Epidemiology and risk factors of urothelial bladder cancer, Eur. Urol., 63, 234, 10.1016/j.eururo.2012.07.033 Murta-Nascimento, 2007, Risk of bladder cancer associated with family history of cancer : do low-penetrance polymorphisms account for the increase in risk ?, Cancer Epidemiol. Biomarkers Prev., 16, 1595, 10.1158/1055-9965.EPI-06-0743 Mucci, 2016, Familial risk and heritability of cancer among twins in nordic countries critical revision of the manuscript for important intellectual content, JAMA, 315, 68, 10.1001/jama.2015.17703 Li, 2017, Standards and guidelines for the interpretation and reporting of sequence variants in cancer: a joint consensus recommendation of the association for molecular pathology, American Society of Clinical Oncology, and College of American Pathologists, J. Mol. Diagn., 19, 4, 10.1016/j.jmoldx.2016.10.002 http://www.ncbi.nlm.nih.gov/clinvar. Ghosh, 2017, Evaluation of in silico algorithms for use with ACMG/AMP clinical variant interpretation guidelines, Genome Biol., 18, 225, 10.1186/s13059-017-1353-5 Eccles, 2015, BRCA1 and BRCA2 genetic testing—pitfalls and recommendations for managing variants of uncertain clinical significance, Ann. Oncol., 26, 2057, 10.1093/annonc/mdv278 Sud, 2017, Genome-wide association studies of cancer: current insights and future perspectives, Nat. Rev. Cancer, 17, 692, 10.1038/nrc.2017.82 Holtzman, 2000, Will genetics revolutionize medicine?, N. Engl. J. Med., 343, 141, 10.1056/NEJM200007133430213 Mork M, 2015, Lynch syndrome: a primer for urologists and panel recommendations, J. Urol., 194, 21, 10.1016/j.juro.2015.02.081 Pradere, 2017, Lynch syndrome in upper tract urothelial carcinoma: significance, screening, and surveillance, Curr. Opin. Urol., 27, 48, 10.1097/MOU.0000000000000340 https://www.nccn.org/professionals/physician_gls/pdf/genetics_colon.pdf. Harper, 2017, Upper tract urothelial carcinomas: frequency of association with mismatch repair protein loss and lynch syndrome, Mod. Pathol., 30, 146, 10.1038/modpathol.2016.171 Metcalfe, 2018, Universal point of care testing for lynch syndrome in patients with upper tract urothelial carcinoma, J. Urol., 199, 60, 10.1016/j.juro.2017.08.002 Robinson, 2019, Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signaling, Nat. Commun., 10, 2977, 10.1038/s41467-019-10873-y Donahu, 2018, Genomic characterization of upper-tract urothelial carcinoma in patients with lynch syndrome, JCO Precis. Oncol., 2018 Skeldon, 2013, Patients with Lynch syndrome mismatch repair gene mutations are at higher risk for not only upper tract urothelial cancer but also bladder cancer, Eur. Urol., 63, 379, 10.1016/j.eururo.2012.07.047 Huang, 2018, Systematic review: an update on the spectrum of urological malignancies in lynch syndrome, Bladder Cancer, 4, 261, 10.3233/BLC-180180 Lim, 2019, Lynch syndrome and urologic malignancies: a contemporary review, Curr. Opin. Urol., 29, 357, 10.1097/MOU.0000000000000639 Siefker-Radtke, 2018, Immunotherapy in metastatic urothelial carcinoma: focus on immune checkpoint inhibition, Nat. Rev. Urol., 15, 112, 10.1038/nrurol.2017.190 Latham, 2019, Microsatellite instability is associated with the presence of lynch syndrome pan-cancer, J. Clin. Oncol., 37, 286, 10.1200/JCO.18.00283 Le, 2017, Mismatch-repair deficiency predicts response of solid tumors to PD-1 blockade, Science, 357, 409, 10.1126/science.aan6733 Marcus, 2019, FDA approval summary: pembrolizumab for the treatment of microsatellite instability-high solid tumors, Clin. Cancer Res., 25, 3753, 10.1158/1078-0432.CCR-18-4070 https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-pembrolizumab-first-tissuesite-agnostic-indication. Vlachostergios, 2017, Germline DNA repair single nucleotide polymorphisms in urothelial cancer patients, J. Urol., 197, e644, 10.1016/j.juro.2017.02.1499 Faltas, 2017, Germline single nucleotide polymorphisms in DNA repair genes in urothelial cancer patients, Cancer Res., 77 http://exac.broadinstitute.org/. Carlo, 2017, Cancer predisposing germline mutations in patients (pts) with urothelial cancer (UC) of the renal pelvis (R-P), ureter (U) and bladder (B), J. Clin. Oncol., 35 Carlo, 2018, DNA damage repair (DDR) germline mutations in patients (Pts) with urothelial carcinoma (UC), J. Clin. Oncol., 36 Carlo, 2019, Cancer Susceptibility Mutations in Patients With Urothelial Malignancies., J. Clin. Oncol. Abou Alaiwi, 2019, Germline variants in urothelial carcinoma: analysis of pathogenic and likely pathogenic variants in 645 subjects, J. Clin. Oncol., 37 https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-germline-brca-mutated-metastatic-breast-cancer. https://www.fda.gov/drugs/fda-approved-olaparib-lynparza-astrazeneca-pharmaceuticals-lp-maintenance-treatment-adult-patients. Złowocka, 2008, Germline mutations in the CHEK2 kinase gene are associated with an increased risk of bladder cancer, Int. J. Cancer., 122, 583, 10.1002/ijc.23099 Madubata, 2017, Identification of potentially oncogenic alterations from tumor-only samples reveals Fanconi anemia pathway mutations in bladder carcinomas, NPJ Genom. Med., 2, 29, 10.1038/s41525-017-0032-5 Nassar, 2019, Germline alterations in urothelial carcinoma (UC) patients with family history of UC, J. Clin. Oncol., 37 Nassar, 2019, Prevalence of pathogenic germline cancer risk variants in high-risk urothelial carcinoma., Genet. Med. Stern, 2009, Polymorphisms in DNA repair genes, smoking, and bladder cancer risk: findings from the international consortium of bladder cancer, Cancer Res., 69, 6857, 10.1158/0008-5472.CAN-09-1091 de Maturana, 2018, Bladder cancer genetic susceptibility. A systematic review, Bladder Cancer, 4, 215, 10.3233/BLC-170159 Moore, 2011, GSTM1 null and NAT2 slow acetylation genotypes, smoking intensity and bladder cancer risk: results from the New England bladder cancer study and NAT2 meta-analysis, Carcinogenesis, 32, 182, 10.1093/carcin/bgq223 Tang, 2012, Mapping of the UGT1A locus identifies an uncommon coding variant that affects mRNA expression and protects from bladder cancer, Hum. Mol. Genet., 21, 1918, 10.1093/hmg/ddr619 Middlebrooks, 2016, Association of germline variants in the APOBEC3 region with cancer risk and enrichment with APOBEC-signature mutations in tumors, Nat. Genet., 48, 1330, 10.1038/ng.3670 Roberts, 2013, An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers, Nat. Genet., 45, 970, 10.1038/ng.2702 Fu, 2014, The 19q12 bladder cancer GWAS signal: association with cyclin E function and aggressive disease, Cancer Res., 74, 5808, 10.1158/0008-5472.CAN-14-1531 Pattison, 2016, Transcription factor KLF5 binds a cyclin E1 polymorphic intronic enhancer to confer increased bladder cancer risk, Mol. Cancer Res., 14, 1078, 10.1158/1541-7786.MCR-16-0123 Torkamani, 2018, The personal and clinical utility of polygenic risk scores, Nat. Rev. Genet., 19, 581, 10.1038/s41576-018-0018-x Garcia-Closas, 2013, Common genetic polymorphisms modify the effect of smoking on absolute risk of bladder cancer, Cancer Res., 73, 2211, 10.1158/0008-5472.CAN-12-2388 Shi, 2019, Systematic evaluation of cancer‐specific genetic risk score for 11 types of cancer in the cancer genome atlas and electronic medical records and genomics cohorts, Cancer Med., 8, 3196, 10.1002/cam4.2143 https://www.uspreventiveservicestaskforce.org/Page/Document/RecommendationStatementFinal/bladder-cancer-in-adults-screening. https://www.cancer.gov/types/bladder/hp/bladder-screening-pdq. https://www.cancer.org/cancer/bladder-cancer/detection-diagnosis-staging/detection.html. Vickers, 2013, Who should be included in a clinical trial of screening for bladder cancer?: a decision analysis of data from the prostate, lung, colorectal and ovarian cancer screening trial, Cancer, 119, 143, 10.1002/cncr.27692 Sweis, 2018, Clinical activity of olaparib in urothelial bladder cancer with DNA damage response gene mutations, JCO Precis. Oncol., 10.1200/PO.18.00264 Foulkes, 2016, Population genetic testing for cancer susceptibility: founder mutations to genomes, Nat. Rev. Clin. Oncol., 13, 41, 10.1038/nrclinonc.2015.173 Klek, 2018, Genetic counseling (GC) and germline (GL) testing rates after adoption of an integrated clinical cancer genetics (CCG) approach to genomics tumor board (GTB)., J. Clin. Oncol., 36, 1511, 10.1200/JCO.2018.36.15_suppl.1511 Hamilton, 2017, Interest and attitudes of patients with advanced cancer with regard to secondary germline findings from tumor genomic profiling, J. Oncol. Pract., 13, e590, 10.1200/JOP.2016.020057